Top Biopharmaceutical Stocks: Performance and Financial Metrics after 2016 Earnings

We have updated the comparison of eight large cap biopharma stocks post 2016 earnings for the period ending 2/10/17. Keep in mind that in January 2016 there was a severe correction with stocks dropping 25-30% with lows being hit in mid-February 2016. But the comparison is post-correction and post-earnings for both periods.

Here are some takeaways:

• Top performing stocks over a one year period are Celgene (CELG) up 18.1%, Amgen (AMGN) up 15.75% and Abbvie (ABBV) up 13.74%.
• Four stocks pay dividends: ABBV, AMGN, BMY and GILD.
• The XBI outperformed all eight stocks over the one year period up 37.66% and the IBB was up 10.98%. The IBB is overweight larger cap stocks.
• The lowest valuations by P/S are GILD, ABBV and BMY.
• The best Q/Q revenue growth for the top line are BMY, ALXN and CELG.
• The best Q/Q EPS growth are BMY, ALXN, CELG and REGN however one should also look at PE ratios.
• Lows for 2016 were hit at Brexit bottom June 27 and November 3 before election results.

After a choppy year in 2016 with two major corrections we would expect less volatility and indices ending positive for 2017.  All data came from Google Finance and FINVIZ.com.